Carles García-Cervera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carles García-Cervera has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Vicente Giner-Galvañ
Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46020 Valencia, Spain
2 shared publications - Amara González Noya
Ourense Univ Hosp Complex, Internal Med Dept, Orense, Spain
1 shared publication Ana Felisa López-Azcona
Infectious Diseases Unit, Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
1 shared publication- Ana Infante-Urrios
Microbiology Section, Hospital Clínico Universitario de San Juan de Alicante, Alicante, Spain
1 shared publication Ana Martínez Mateo
Chief of Public Health Agency of Catalonia, Department of Health, Barcelona, Spain
1 shared publicationAna Vázquez González
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain; CIBER de Epidemiología y Salud Publica (CIBERESP), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in Infection & Chemotherapy
- Vol. 56 (3) , 351-360
Impact of Implementing an Antimicrobial Stewardship Program for Optimizing Antibiotic Treatment in Gram-negative Bacilli Bacteremia
García-Cervera C, et al. Infect Chemother. 2024 Jul;56:e30. https://doi.org/10.3947/ic.2024.0026
- 1 January 2024
- Published by XMLink in Infection & Chemotherapy
- Vol. 56 (3) , 351-360
Open AccessImpact of Implementing an Antimicrobial Stewardship Program for Optimizing Antibiotic Treatment in Gram-negative Bacilli Bacteremia
García-Cervera C, et al. Infect Chemother. 2024 Jul;56:e30. https://doi.org/10.3947/ic.2024.0026
- 20 July 2023
- Published by Taylor & Francis in Infectious Diseases
- Vol. 55 (11) , 798-802
Report on the first two confirmed autochthonous cases of West Nile virus encephalitis in Catalonia, Spain
West Nile virus (WNV) is a mosquito-borne flavivirus that can cause Central Nervous System infection in humans. Previous autochthonous cases of WNV encephalitis have been described in Spain, but none in Catalonia. We report on the first two autochthonous cases of encephalitis in humans caused by the West Nile virus (WNV) diagnosed in Catalonia (northeastern region of Spain). An old married couple presented with clinical and biological signs compatible with viral encephalitis. Acute and convalescent serum samples showed IgM and IgG positivity for WNV. In addition, IgM was also detected in cerebrospinal fluid in the male patient. The serological results were later confirmed by microneutralization assays. WNV infection must be considered in patients presenting with meningoencephalitis with viral CSF characteristics when common pathogens are excluded.
- 20 July 2023
- Published by Taylor & Francis in Infectious Diseases
- Vol. 55 (11) , 798-802
Report on the first two confirmed autochthonous cases of West Nile virus encephalitis in Catalonia, Spain
West Nile virus (WNV) is a mosquito-borne flavivirus that can cause Central Nervous System infection in humans. Previous autochthonous cases of WNV encephalitis have been described in Spain, but none in Catalonia. We report on the first two autochthonous cases of encephalitis in humans caused by the West Nile virus (WNV) diagnosed in Catalonia (northeastern region of Spain). An old married couple presented with clinical and biological signs compatible with viral encephalitis. Acute and convalescent serum samples showed IgM and IgG positivity for WNV. In addition, IgM was also detected in cerebrospinal fluid in the male patient. The serological results were later confirmed by microneutralization assays. WNV infection must be considered in patients presenting with meningoencephalitis with viral CSF characteristics when common pathogens are excluded.
- 21 July 2021
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (11) , 3478-3486
Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry
Background Venous thrombotic events (VTE) are frequent in COVID-19, and elevated plasma D-dimer (pDd) and dyspnea are common in both entities. Objective To determine the admission pDd cut-off value associated with in-hospital VTE in patients with COVID-19. Methods Multicenter, retrospective study analyzing the at-admission pDd cut-off value to predict VTE and anticoagulation intensity along hospitalization due to COVID-19. Results Among 9386 patients, 2.2% had VTE: 1.6% pulmonary embolism (PE), 0.4% deep vein thrombosis (DVT), and 0.2% both. Those with VTE had a higher prevalence of tachypnea (42.9% vs. 31.1%; p = 0.0005), basal O2 saturation 9/L; p = 0.0013). A pDd cut-off of 1.1 μg/ml showed specificity 72%, sensitivity 49%, positive predictive value (PPV) 4%, and negative predictive value (NPV) 99% for in-hospital VTE. A cut-off value of 4.7 μg/ml showed specificity of 95%, sensitivity of 27%, PPV of 9%, and NPV of 98%. Overall mortality was proportional to pDd value, with the lowest incidence for each pDd category depending on anticoagulation intensity: 26.3% for those with pDd >1.0 μg/ml treated with prophylactic dose (p < 0.0001), 28.8% for pDd for patients with pDd >2.0 μg/ml treated with intermediate dose (p = 0.0001), and 31.3% for those with pDd >3.0 μg/ml and full anticoagulation (p = 0.0183). Conclusions In hospitalized patients with COVID-19, a pDd value greater than 3.0 μg/ml can be considered to screen VTE and to consider full-dose anticoagulation.
- 21 July 2021
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 36 (11) , 3478-3486
Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry
Background Venous thrombotic events (VTE) are frequent in COVID-19, and elevated plasma D-dimer (pDd) and dyspnea are common in both entities. Objective To determine the admission pDd cut-off value associated with in-hospital VTE in patients with COVID-19. Methods Multicenter, retrospective study analyzing the at-admission pDd cut-off value to predict VTE and anticoagulation intensity along hospitalization due to COVID-19. Results Among 9386 patients, 2.2% had VTE: 1.6% pulmonary embolism (PE), 0.4% deep vein thrombosis (DVT), and 0.2% both. Those with VTE had a higher prevalence of tachypnea (42.9% vs. 31.1%; p = 0.0005), basal O2 saturation 9/L; p = 0.0013). A pDd cut-off of 1.1 μg/ml showed specificity 72%, sensitivity 49%, positive predictive value (PPV) 4%, and negative predictive value (NPV) 99% for in-hospital VTE. A cut-off value of 4.7 μg/ml showed specificity of 95%, sensitivity of 27%, PPV of 9%, and NPV of 98%. Overall mortality was proportional to pDd value, with the lowest incidence for each pDd category depending on anticoagulation intensity: 26.3% for those with pDd >1.0 μg/ml treated with prophylactic dose (p < 0.0001), 28.8% for pDd for patients with pDd >2.0 μg/ml treated with intermediate dose (p = 0.0001), and 31.3% for those with pDd >3.0 μg/ml and full anticoagulation (p = 0.0183). Conclusions In hospitalized patients with COVID-19, a pDd value greater than 3.0 μg/ml can be considered to screen VTE and to consider full-dose anticoagulation.